公开(公告)号：US20210388118A1

公开(公告)日：2021-12-16

申请号：US17458945

申请日：2021-08-27

申请人： Zhejiang Shimai Pharmaceutical Co. Ltd.

发明人： Weizao Chen ,  Yanping Wang ,  Zuoxiang Xiao

IPC分类号： C07K16/46 ,  C07K16/28 ,  A61P35/00

摘要： The present invention provides recombinant bispecific antibodies designed to bind to a surface antigen on target cells and to an activating component on immune cells such as T cells. The bispecific antibodies comprise two polypeptide chains that contain Fv and Fab as antigen-binding fragments and a modified Fc region to facilitate heterodimer formation In one embodiment, the bispecific antibodies further comprise protease cleavage sites and/or motifs that would cause steric occlusion of the antigen binding sites so that the antibodies would be activated only in a specific environment, e.g. in the vicinity of a tumor. In another embodiment, the bispecific antibodies comprise modified sequences that confer reduced binding affinity to CDS and/or cross-reactive binding to CDS on cells from different species.

公开(公告)号：US20230357410A1

公开(公告)日：2023-11-09

申请号：US17312258

申请日：2019-12-20

申请人： Zhejiang Shimai Pharmaceutical Co.,Ltd.

发明人： Weizao Chen ,  Yanping Wang ,  Zuoxiang Xiao

IPC分类号： A61K39/00 ,  A61P35/00 ,  C07K14/71 ,  C07K14/82 ,  C07K16/28

CPC分类号： C07K16/2863 ,  A61P35/00 ,  C07K14/71 ,  C07K14/82 ,  C07K16/2809 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/73 ,  C07K2317/92 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/50

摘要： The present invention provides recombinant bispecific antibodies designed to bind to a surface antigen on target cells and to an activating component on immune cells such as T cells. The bispecific antibodies comprise two polypeptide chains that contain Fv and Fab as antigen¬ binding fragments and a modified Fc region to facilitate heterodimer formation. In one embodiment, the bispecific antibodies further comprise protease cleavage sites and/or motifs that would cause steric occlusion of the antigen binding sites so that the antibodies would be activated only in a specific environment, e.g. in the vicinity of a tumor. In another embodiment, the bispecific antibodies comprise modified sequences that confer reduced binding affinity to CDS and/or cross-reactive binding to CDS on cells from different species.

公开(公告)号：US11339218B2

公开(公告)日：2022-05-24

申请号：US16611986

申请日：2018-05-09

申请人： Zhejiang Shimai Pharmaceutical Co., Ltd.

发明人： Weizao Chen ,  Tao Fu ,  Zuoxiang Xiao

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61K39/395 ,  A61K39/00

摘要： The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG3. In certain embodiments, the antibodies bind both human and monkey LAG3 but do not bind mouse LAG3. The invention provides anti-LAG3 antibodies that can inhibit the binding of LAG3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for stimulating an immune response, as well as methods for treating cancer using an anti-LAG3 antibody of the invention.